Federal False Claims Act & Qui Tam Whistleblower Lawyers Texas | 31 U.S.C. §§ 3729-3733

31 U.S.C. §§ 3729-3733 in overview

The federal False Claims Act is codified at 31 U.S.C. §§ 3729-3733. The framework operates through five interconnected provisions:

• § 3729 — Substantive liability. Defines the prohibited conduct (knowing presentation of false claims, knowing use of false records material to false claims, conspiracy, reverse false claims). Establishes treble damages and civil penalties.
• § 3730 — Civil actions for false claims. The procedural framework. Subsection (a) addresses government actions; subsection (b) addresses qui tam relator actions; subsection (d) addresses the relator share; subsection (e) addresses the public disclosure bar and other jurisdictional restrictions; subsection (h) is the anti-retaliation provision.
• § 3731 — False claims procedure. Establishes the statute of limitations framework. Section 3731(b) provides the six-year/three-year/ten-year limitations structure addressed in Cochise Consultancy, Inc. v. United States ex rel. Hunt, 587 U.S. 262 (2019).
• § 3732 — False claims jurisdiction. Establishes federal court jurisdiction and venue. Authorizes state intervention in FCA actions involving state proceeds.
• § 3733 — Civil investigative demands. Authorizes the Attorney General to issue civil investigative demands for documents, written interrogatories, and oral testimony in connection with FCA investigations.

The integrated framework operates differently from state retaliation statutes in several distinctive ways:

Federal court jurisdiction. FCA actions are heard in federal court. State court jurisdiction is foreclosed. The federal procedural framework — Federal Rules of Civil Procedure, federal evidence rules, federal pleading standards — applies throughout.

Substantive and anti-retaliation provisions integrated. The same statutory framework provides both the underlying substantive liability for the fraud (§ 3729) and the anti-retaliation cause of action protecting reporters (§ 3730(h)). The qui tam relator share under § 3730(d) sits between them, providing independent private recovery alongside the anti-retaliation framework.

Government intervention dynamics. FCA cases proceed through an investigation phase during which the government decides whether to intervene. The intervention decision substantially affects the case trajectory, the settlement dynamics, and the relator share calculation.

Filing under seal. Qui tam complaints are filed under seal — meaning the relator cannot disclose the existence of the case to the employer or to any other person except as required for the government investigation. The seal typically extends for 60 days but is routinely extended for years during government investigation.

§ 3729 — What constitutes a false claim

Section 3729(a)(1) defines the substantive conduct that constitutes a violation of the FCA. The framework reaches a broad range of conduct affecting federal programs:

The scienter requirement

The “knowingly” element of § 3729 is defined in § 3729(b)(1) to include actual knowledge, deliberate ignorance, and reckless disregard. The Supreme Court in United States ex rel. Schutte v. SuperValu Inc., 598 U.S. 739 (2023), confirmed that the FCA scienter standard is subjective — what the defendant actually knew or believed about the falsity of the claim, not what an objectively reasonable person would have known. The Schutte decision rejected defendants’ efforts to use objective reasonableness as a defense where the defendant’s actual subjective belief was that the claim was false.

The materiality requirement

Sections § 3729(a)(1)(B) and (G) require that the false statement or record be “material to” the false claim or to the obligation. The Supreme Court in Universal Health Services, Inc. v. United States ex rel. Escobar, 579 U.S. 176 (2016), addressed materiality in the context of implied certification theory. The Court held that materiality is a “demanding” standard but reaffirmed that violations of statutes, regulations, or contractual requirements that the government would consider material — including conditions of payment — satisfy the FCA materiality requirement. The Escobar decision is the controlling authority on implied certification FCA theory, particularly relevant in healthcare contexts where reimbursement is conditioned on regulatory compliance.

Categories of substantive violations

The § 3729 framework reaches a wide range of conduct:

• Direct false claims — claims that overstate the goods or services provided, misrepresent the entity providing them, or claim payment for non-existent services
• Implied certification — claims that implicitly represent compliance with material statutory, regulatory, or contractual requirements when such compliance was lacking
• Express certification — claims accompanied by express certifications of compliance that were false
• Promissory fraud — claims accompanied by representations about future conduct that were false when made
• Reverse false claims — knowingly retaining government overpayments or knowingly avoiding obligations to pay the government
• Conspiracy — agreement to commit any of the above with overt act in furtherance

§ 3730(b) — Private relator standing

The qui tam framework is the FCA’s distinctive feature. No state retaliation statute provides a parallel private-relator recovery mechanism. The framework allows a private person — the relator — to file a civil action on behalf of the United States, with the relator entitled to a substantial share of any recovery.

How qui tam actions proceed

The qui tam procedural framework operates through specific steps:

1. The relator files the complaint under seal. The relator files a sealed complaint in federal district court along with a written disclosure of substantially all material evidence and information the relator possesses. The complaint and disclosure go to the U.S. Attorney for the district and to the U.S. Attorney General.
2. The complaint remains sealed during government investigation. The complaint is initially sealed for 60 days under § 3730(b)(2). The seal is routinely extended — sometimes for years — while the government investigates. During the seal period, the relator typically cannot disclose the existence of the case to anyone except as authorized by the court.
3. The government investigates. The Department of Justice (typically the U.S. Attorney’s office and the Civil Division Fraud Section) investigates the allegations, often working with the relevant agency inspector general (HHS-OIG, DOD-IG, USDA-IG, etc.). The investigation may include witness interviews, document subpoenas, civil investigative demands under § 3733, and parallel grand jury investigation in criminal-track matters.
4. The government decides whether to intervene. Under § 3730(b)(4), the government must elect whether to intervene before the seal is lifted. The intervention decision is consequential: if the government intervenes, the case proceeds with the government as the primary party; if not, the relator may proceed alone or may dismiss.
5. The case proceeds to disposition. Intervened cases typically resolve through settlement or judgment with the government leading the litigation. Non-intervened cases proceed with the relator’s counsel leading, with the government retaining the right to intervene later for good cause.
6. The relator share is calculated. Upon resolution, the relator share under § 3730(d) is calculated based on the relator’s contribution, the public disclosure analysis, and the intervention status.

The relator share under § 3730(d)

Several factors affect the within-range share calculation:

• The relator’s contribution to the investigation and prosecution. Substantial cooperation, document production, witness identification, and litigation support support higher shares.
• The relator’s role in originally identifying the fraud. Original-source relators with direct and independent knowledge typically receive higher shares.
• The public disclosure analysis. Where the action is based primarily on disclosures of specific information from federal sources, the relator share may be reduced to no more than 10% under § 3730(d)(1).
• Bar to share for culpable relators. Under § 3730(d)(3), where the relator planned and initiated the underlying fraud, the share may be reduced or eliminated. Where the relator is convicted of criminal conduct arising from the fraud, no share is awarded.

§ 3730(h) — The federal anti-retaliation provision

Section 3730(h) provides the FCA’s anti-retaliation cause of action. The provision protects employees, contractors, and agents who engage in protected activity from retaliation by their employer or contracting entity.

The two-pronged protected activity framework

Section § 3730(h) reaches two categories of protected activity:

Lawful acts in furtherance of an FCA action. Filing a qui tam complaint is the central example, but the framework reaches a broader range of pre-filing investigative conduct — gathering documents, identifying witnesses, consulting with counsel about a potential FCA claim, and other preparation for FCA litigation. Workers who are taking concrete steps toward filing FCA action are within § 3730(h)’s protection even before the action is filed.

Other efforts to stop FCA violations. The “other efforts” category is significant — it reaches workers who report fraud internally, refuse to participate in fraud, raise concerns about billing practices, push back against compliance violations, or otherwise oppose conduct they reasonably believe violates the FCA. The protection does not require that the worker have filed or intended to file a qui tam action. Internal compliance reporting, refusal to participate in fraud, and other efforts to stop violations all qualify.

Damages under § 3730(h)

The § 3730(h) damages framework is distinctive in several respects:

The 2x back pay multiplier is automatic. Unlike Texas exemplary damages frameworks that require additional findings of awareness or willfulness, the § 3730(h) doubling of back pay applies upon any successful retaliation claim. No additional showing is required to access the multiplier.

“Special damages” reaches consequential harm. The framework reaches mental anguish, professional reputation harm, loss of professional standing, and other consequential damages flowing from the retaliation. The category is broader than direct economic loss.

Attorney’s fees are mandatory. The fee-shifting provision applies upon prevailing-plaintiff status. The cumulative attorney’s fees can be substantial in protracted federal court litigation.

Reinstatement with seniority. The framework specifically authorizes equitable relief restoring the worker to position with appropriate seniority — addressing both the lost employment and the lost career trajectory.

The § 3730(h) statute of limitations

Under § 3730(h)(3), the statute of limitations for § 3730(h) retaliation claims is three years from the date of the retaliatory action. The three-year window is substantially more generous than most state retaliation statutes — §161.134’s 179-day window, §260A.014’s 90-day standard window, and the §301.413 framework. For workers who have both federal FCA retaliation claims and parallel state claims, the federal three-year window provides a longer runway for the federal claim while the state claims operate on shorter windows. Coordinated filing strategy requires attention to all operative windows.

The Texas Medicaid Fraud Prevention Act (Tex. Hum. Res. Code Ch. 36)

The Texas Medicaid Fraud Prevention Act provides the state-level parallel to the federal FCA, with substantially similar structure adapted to the Texas Medicaid program. The framework operates alongside the federal FCA in most healthcare fraud cases — Medicaid funds typically include both federal and state components, with parallel relator actions available.

Key MFPA provisions

• Substantive liability under Tex. Hum. Res. Code § 36.002. Prohibits making false statements or misrepresentations to the Medicaid program, presenting claims for services not provided, presenting claims that violate Medicaid rules, and similar conduct.
• Qui tam standing under § 36.101 et seq. Private relators may file Medicaid fraud actions on behalf of the State of Texas. The procedural framework parallels the federal FCA — sealed complaint, government investigation period, intervention decision, relator share calculation.
• Relator share. The Texas MFPA provides relator share provisions analogous to the federal FCA framework.
• Damages. Two times the amount of damages plus civil penalties similar in structure to the federal FCA’s treble damages and per-claim penalties.
• Anti-retaliation under § 36.115. Provides anti-retaliation protection for Medicaid fraud reporters, with damages framework including back pay, reinstatement, and attorney’s fees.

How the FCA and MFPA stack

In healthcare fraud cases involving the Medicaid program, the FCA and the MFPA typically operate concurrently:

• The federal FCA reaches federal Medicaid matching funds. The federal share of Medicaid funding (typically about 60-70% of total Medicaid expenditures) is reached by the federal FCA.
• The Texas MFPA reaches state Medicaid funds. The state share is reached by the MFPA framework.
• Parallel qui tam actions are common. Relators with knowledge of Medicaid fraud frequently file both federal FCA and Texas MFPA actions, with the recovery allocated between the federal and state components and the relator share allocated correspondingly.
• Coordination with the Texas Attorney General’s Medicaid Fraud Control Unit (MFCU). The Texas MFCU has jurisdiction over MFPA matters and typically coordinates with the federal Department of Justice in parallel investigations.

Healthcare FCA — the largest category of qui tam recoveries

Healthcare fraud is the largest category of FCA recoveries by volume. The Department of Justice’s annual FCA statistics consistently show healthcare-related recoveries accounting for the substantial majority of total FCA recoveries — often 70% or more of annual totals. Healthcare workers across nearly every clinical and administrative role have potential exposure to fraud they may have reasonable cause to believe is occurring.

Major healthcare FCA contexts include:

How qui tam cases proceed from intake to disposition

Qui tam cases proceed through a distinctive procedural framework that differs substantially from ordinary federal civil litigation. Several procedural features warrant particular attention.

Pre-filing investigation and counsel engagement

Before filing a qui tam complaint, careful pre-filing investigation is essential. The investigation should address:

• The substantive FCA theory. Identifying the specific § 3729 violation theory — direct false claims, implied certification under Escobar, reverse false claims, conspiracy, or some combination.
• The materiality analysis under Escobar. Establishing that the underlying non-compliance was material to the government’s payment decision.
• The scienter analysis under Schutte. Establishing the defendant’s actual knowledge, deliberate ignorance, or reckless disregard.
• The damages analysis. Quantifying the government’s damages from the underlying fraud — typically the amount of false claims paid.
• The public disclosure analysis. Confirming that the relator’s claims are not foreclosed by the public disclosure bar or, where they are, establishing original-source status.
• The first-to-file analysis. Confirming that no other relator has filed a related action on the same facts.

Filing under seal

The complaint is filed under seal in federal district court. Under § 3730(b)(2), the complaint is initially sealed for 60 days. The seal is routinely extended — sometimes for multiple years — during the government investigation. During the seal period, the relator cannot disclose the existence of the case to the employer, to coworkers, to family members, or to others except as authorized by the court.

The seal has significant implications for the relator’s parallel anti-retaliation claim. Where the relator faces retaliation during the seal period, the § 3730(h) anti-retaliation cause of action operates alongside the underlying qui tam claim — but the relator cannot publicly invoke the qui tam case as the basis for the retaliation. The § 3730(h) protected activity framework reaches “other efforts to stop violations” that may have been visible to the employer even where the formal qui tam filing was sealed.

Government investigation

During the seal period, the Department of Justice (typically the U.S. Attorney for the district and the Civil Division Fraud Section) investigates the allegations. The investigation may include:

• Witness interviews coordinated with the relator’s counsel
• Document subpoenas and civil investigative demands under § 3733
• Coordination with the relevant agency inspector general (HHS-OIG, DOD-IG, USDA-IG, USPS-OIG, etc.)
• Parallel grand jury investigation in matters with potential criminal exposure
• Negotiation with defense counsel where the case is moving toward settlement

The investigation phase is typically the longest portion of a qui tam case. Two to five years is not unusual. The relator’s counsel supports the investigation through periodic submissions, witness preparation, document collection, and analytical support.

The intervention decision

Before the seal is lifted, the government must elect whether to intervene under § 3730(b)(4). The intervention decision is consequential:

• Intervened cases. The government takes the lead and proceeds with the litigation. Settlement negotiations and litigation strategy are primarily driven by DOJ. The relator’s role becomes supportive. The relator share under § 3730(d)(1) is 15-25%.
• Non-intervened cases. The relator may proceed alone, dismiss, or settle. The relator’s counsel takes the lead. The relator share under § 3730(d)(2) is 25-30% — but the relator bears the cost and risk of independent litigation. The government retains the right to intervene later for good cause.
• Government dismissal. Under United States ex rel. Polansky v. Executive Health Resources, Inc., 599 U.S. 419 (2023), the government may move to dismiss qui tam actions even after declining to intervene, subject to Federal Rule of Civil Procedure 41 considerations. The Polansky decision affirmed substantial government authority over qui tam dismissal.

Settlement and judgment

The substantial majority of qui tam cases resolve through settlement rather than judgment. Settlement negotiations involve multiple parties (the government, the defendant, and the relator) and address multiple components (the underlying damages calculation, civil penalties, the relator share, and any non-monetary remedies including corporate integrity agreements). The relator’s counsel advocates for the relator’s interests in settlement negotiations, including the relator share allocation.

Public disclosure bar and first-to-file rule

Two jurisdictional restrictions affect qui tam standing — the public disclosure bar under § 3730(e)(4) and the first-to-file rule under § 3730(b)(5). Both require careful pre-filing analysis.

The public disclosure bar

The “original source” exception under § 3730(e)(4)(B) reaches relators who have direct and independent knowledge of the information on which the allegations are based and who voluntarily provided the information to the government before filing the action, or who have knowledge that materially adds to the publicly disclosed information.

The public disclosure analysis is fact-intensive and litigation over the bar’s application is common. Relators with knowledge gained through employment typically satisfy the direct-and-independent-knowledge requirement, but the public disclosure analysis still requires careful pre-filing evaluation of whether the underlying allegations have been publicly disclosed in qualifying forums.

The first-to-file rule

The first-to-file rule creates urgency in qui tam practice. Where multiple potential relators have knowledge of the same fraud, the first to file in federal court typically establishes relator standing while subsequent filers may be foreclosed. The first-to-file rule operates alongside the public disclosure bar to ensure that only one relator action proceeds on a particular fraud pattern, with the relator share allocated to the first-filed relator.

§ 3731(b) and the Cochise limitations framework

The FCA statute of limitations framework is more complex than most state retaliation statutes. Section 3731(b) provides three potentially applicable time periods, with the Supreme Court’s decision in Cochise Consultancy clarifying how the framework operates in qui tam cases.

The Cochise framework

In Cochise Consultancy, Inc. v. United States ex rel. Hunt, 587 U.S. 262 (2019), the Supreme Court resolved a circuit split on the application of § 3731(b)(2) to qui tam cases where the government does not intervene. The Court held that relators may invoke both § 3731(b)(1) and § 3731(b)(2), even in non-intervened cases. The framework provides relators with substantial flexibility:

• Six years from the violation — the baseline limitation under § 3731(b)(1).
• Three years from the date government officials charged with responsibility knew or should have known of the material facts — under § 3731(b)(2). This subsection extends the limitations period where the underlying fraud was concealed or where government knowledge developed after the violation.
• Ten years maximum. Regardless of the other provisions, no FCA action may be brought more than ten years after the violation.
• Whichever occurs last. The relator may use whichever of the (b)(1) or (b)(2) windows is longer, subject to the ten-year cap.

The § 3730(h) limitations period

Section 3730(h)(3) provides a separate three-year statute of limitations specifically for retaliation claims, running from the date of the retaliatory action. The three-year window is substantially more generous than most state retaliation statutes. Workers with parallel state and federal retaliation claims must coordinate the filing strategy across the shorter state windows and the longer federal window.

Patterns of FCA retaliation

FCA retaliation cases involve patterns specific to the federal whistleblower context. The patterns that recur with enough frequency to be treated as a doctrinal category include:

How the FCA framework stacks with Texas and federal retaliation statutes

The federal FCA framework operates concurrently with state and federal anti-retaliation statutes in many contexts. The stacking produces overlapping protections, multiple damages frameworks, and parallel limitations periods.

The structural significance of the FCA framework

The federal False Claims Act framework is more substantively powerful than any state retaliation framework. Several structural features warrant attention.

The qui tam framework creates private enforcement leverage. No state retaliation statute provides a parallel relator-share recovery mechanism. The relator share — 15-25% in intervened cases, 25-30% in non-intervened cases — provides substantial private incentive for whistleblowers and substantial private resources for relator’s counsel to develop FCA matters thoroughly. The aggregate effect is that FCA enforcement substantially exceeds what the government could accomplish through internal enforcement alone.

The treble damages plus per-claim penalties produce massive defendant exposure. Healthcare fraud cases frequently involve hundreds or thousands of false claims over multi-year periods. Treble damages on the underlying claim amount, plus civil penalties per claim, can produce nine- and ten-figure exposure for healthcare operators. The settlement dynamics reflect this exposure — major healthcare fraud settlements regularly exceed $100 million, and several exceed $1 billion.

The § 3730(h) anti-retaliation framework is exceptionally broad. The “employees, contractors, and agents” coverage reaches workers across employment structures. The “lawful acts in furtherance of an action” plus “other efforts to stop violations” framing reaches both formal qui tam relators and workers engaged in internal compliance reporting. The 2x back pay multiplier, special damages, mandatory attorney’s fees, and reinstatement create a damages framework that exceeds most state retaliation statutes.

The three-year statute of limitations for § 3730(h) provides extended preservation window. Where Texas state retaliation statutes operate on 90-day, 179-day, or two-year windows, § 3730(h)’s three-year window provides relators with substantially more time to file. The extended window is particularly consequential where workers are unaware of their FCA rights or where the connection between protected activity and retaliation becomes clear only over time.

The cross-statute stacking is particularly powerful. A healthcare worker reporting Medicaid fraud may have claims under § 3730(h) (FCA), the Texas MFPA, §161.134 (hospital) or §260A.014 (LTC), §301.413 (NPA) for nurses, §505.603 for social workers, SOX §806 for publicly-traded operators, and Sabine Pilot common law. The cumulative damages, presumptions, and procedural advantages across stacked statutes provide substantial leverage in settlement and litigation.

The major Supreme Court FCA cases address the framework’s reach. Escobar (implied certification), Schutte (subjective scienter), Cochise (limitations), and Polansky (government dismissal authority) have all clarified the framework in recent years. The doctrinal landscape continues to evolve, and FCA practice requires ongoing attention to developing case law in the federal courts.

How the firm approaches FCA retaliation matters

Doyle Dennis Avery LLP represents both qui tam relators and § 3730(h) retaliation plaintiffs across healthcare, federal contracting, and other federal program contexts. The firm’s FCA practice covers the complete federal-court qui tam representation — pre-filing investigation including the public disclosure bar analysis, the first-to-file analysis, and the original-source determination; preparation and filing of the sealed complaint under § 3730(b); coordination with the Department of Justice and the relevant agency inspector general through the government investigation period and the intervention decision; settlement negotiation including relator share advocacy; and litigation through trial in non-intervened or partially intervened cases. The firm also handles parallel Texas Medicaid Fraud Prevention Act practice under Tex. Hum. Res. Code Ch. 36, with parallel state-court filings for Medicaid fraud matters involving Texas state funds.

For § 3730(h) anti-retaliation matters, the firm represents employees, contractors, and agents who faced termination, suspension, demotion, or other adverse action after engaging in FCA-protected activity — including both formal qui tam relators and workers engaged in internal compliance reporting, refusal to participate in fraud, or other efforts to stop FCA violations. The § 3730(h) framework operates concurrently with applicable Texas retaliation statutes (§161.134, §260A.014, §301.413, §505.603), and the firm coordinates the multi-statute claim development across all operative frameworks. Where a single matter involves both an underlying qui tam claim and a § 3730(h) retaliation claim, the firm advances both within a single integrated representation.

Two of the firm’s named partners are board certified by the Texas Board of Legal Specialization. Jeffrey Avery is board certified in Labor and Employment Law. Michael Patrick Doyle is board certified in Personal Injury Trial Law. The firm’s published Texas appellate authority in Salas v. Fluor Daniel Services Corp., 616 S.W.3d 137, provides directly transferable authority for piercing “performance” and “reduction-in-force” pretexts that recur in FCA retaliation cases. The firm has direct federal contractor whistleblower representation experience through NDAA §4712 work at federally funded ORR Unaccompanied Children Program facilities — transferable to FCA practice in federal contractor contexts.

The firm’s intake process for FCA matters typically opens with a confidential initial consultation. For qui tam relator candidates, documentation review focuses on the substantive fraud evidence — claims data, billing records, internal communications regarding billing practices, compliance audits and findings, Stark and AKS relationship analysis where applicable, and the materiality analysis under Escobar. For § 3730(h) retaliation matters, documentation review focuses on the protected-activity record across all applicable frameworks, the adverse-action timeline, the worker’s professional history, employment paperwork including arbitration agreement analysis, any documentation of compliance reporting or refusal to participate in fraud, and any parallel licensing board or regulatory matter. A written intake analysis identifies the operative statutes (typically including § 3729 substantive theory and § 3730(h) for the retaliation component, plus state retaliation statutes and the Texas MFPA parallel), the qui tam standing analysis including public disclosure, first-to-file, and original-source considerations, the cumulative presumption and damages analysis, the limitations posture across each framework, and the procedural sequencing including coordination with any parallel licensing board defense. Where the matter meets the firm’s criteria, representation proceeds on a contingency basis.

What FCA whistleblowers ask